Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Smith, Ellen Mary Lavoie

University Of Alabama At Birmingham
United States

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study 5R01CA235726-07 Brennan Streck, Ph.D., RN, M.P.H.
Smith, Ellen Mary Lavoie

University Of Alabama At Birmingham
United States

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study 5R01CA235726-07 Brennan Streck, Ph.D., RN, M.P.H.
Smith, Jennifer Susan

Univ Of North Carolina Chapel Hill
United States

UNC CASCADE Network Research Base 5UG1CA275403-04 Maria Silvina Frech, Ph.D., M.S.
Sohl, Stephanie Jean

Wake Forest University Health Sciences
United States

REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE) 5R01CA266995-04 Goli Samimi, Ph.D., M.P.H.
Sohl, Stephanie Jean

Wake Forest University Health Sciences
United States

REmotely-delivered Supportive Programs for Improving surgical pain and disTrEss (RESPITE) 5R01CA266995-04 Goli Samimi, Ph.D., M.P.H.
Somers, Tamara J

Duke University
United States

A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial 5R01CA237892-05 Brennan Streck, Ph.D., RN, M.P.H.
Somers, Tamara J

Duke University
United States

A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial 5R01CA237892-05 Brennan Streck, Ph.D., RN, M.P.H.
Song, Ming

University Of Louisville
United States

Dietary fructose and NASH/HCC progression 5R21CA290420-02 Amit Kumar, Ph.D.
Sorror, Mohamed

Fred Hutchinson Cancer Center
United States

Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality 5R01CA227092-06 Marjorie Perloff, M.D.
Sorror, Mohamed

Fred Hutchinson Cancer Center
United States

Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality 5R01CA227092-06 Marjorie Perloff, M.D.
Sorror, Mohamed

Fred Hutchinson Cancer Center
United States

Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality 5R01CA227092-06 Marjorie Perloff, M.D.
Spector, Tim

King'S College London
United States

PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors 1OT2CA297289-01 Asad Umar, D.V.M., Ph.D.
Spiegel, Brennan

Cedars-Sinai Medical Center
United States

Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes 5R01CA252211-05 Rachel Altshuler, Ph.D.
Spiegel, Brennan

Cedars-Sinai Medical Center
United States

Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes 5R01CA252211-05 Rachel Altshuler, Ph.D.
Stachler, Matthew D

University Of California, San Francisco
United States

Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus 3R37CA269649-03S1 Matthew Young, Ph.D.